Using chemical process simulation to design industrial ecosystems

Chemical process simulation (CPS) software has been widely used by chemical (process) engineers to design, test, optimise, and integrate process plants. It is expected that industrial ecologists to bring these same problem-solving benefits to the design and operation of industrial ecosystems can use CPS. This paper provides industrial ecology researchers and practitioners with an introduction to CPS and an overview of chemical engineering design principles. The paper highlights recent research showing that CPS can be used to model industrial ecosystems, and discusses the benefits of using CPS to address some of the technical challenges facing companies participating in an industrial ecosystem. CPS can be used to (i) quantitatively evaluate and compare the potential environmental and financial benefits of material and energy linkages; (ii) solve general design, retrofit, or operational problems; (iii) help to identify complex and often counter-intuitive solutions; and (iv) evaluate what-if scenarios. CPS should be a useful addition to the industrial ecology toolbox.     

Die Anwendung von molekulargenetischen Techniken in der Neurochemie

Research in molecular neurobiology has recently entered a new phase of rapid development as a result of the application of the techniques of molecular genetics. This is illustrated by recent work on the electric ray (Torpedo marmorata and T. californica), whose electric organ is a rich source of cholinergic synapses. Other examples from recent literature of the application of the recombinant DNA technique to the mammalian central nervous system are given and possible future developments are discussed.     

Detecting neural tube defects by amniocentesis between 11 and 15 weeks' gestation

Forty-two open neural tube defects (NTDs) were identified in our series of 7440 amniocenteses tested between 11 and 15 weeks of gestation. Using a cut-off of ≥2.0 MOM, the detection rate for open NTDs was 95 per cent; 100 per cent each for anencephaly and spina bifida; and 78 per cent for encephalocele. Two encephaloceles had AFP levels less than 2.0 MOM and negative AChEs. Thirty-four (81 per cent) of these NTDs were tested between 13 and 15 weeks and 8 (19 per cent) before 13 weeks. There were 0.6 per cent false positives by AFP (excluding serious abnormalities and fetal death) and 0.1 per cent after AChE. The likelihood of an open NTD after an elevated AFP (≥2.0 MOM) was 24 and 77 per cent for any serious abnormality. These results, when combined with an earlier study, indicate that amniotic fluid AFP appears to be as sensitive a test for open NTDs between 13 and 15 weeks as between 16 and 20 weeks. Additional experience is necessary to determine this before 13 weeks.     

Prenatal diagnosis of inborn errors in peroxisomal β-oxidation

In recent years, an increasing number of inherited diseases in man have been recognized in which there is an impairment in the peroxisomal β-oxidation of very-long-chain fatty acids. In general, these disorders are associated with severe neurological and physical abnormalities and death within the first years of life. In this paper we describe our experience with regard to the prenatal diagnosis of a number of different inborn errors of peroxisomal β-oxidation. Eleven pregnancies at risk were monitored by measuring very-long-chain fatty acid levels as well as very-long-chain fatty acid β-oxidation in cultured chorionic villous fibroblasts and/or amniotic fluid cells. Five affected fetuses were identified. It is concluded that prenatal diagnosis in this group of diseases can be done reliably using cultured chorionic villous fibroblasts or amniotic fluid cells.     

Trisomy 7 in chorionic villi: Follow-up studies of pregnancy,normal child,and placental clonal anomalies

Cytogenetic study of chorionic villi sampled because of advanced maternal age revealed, after overnight culture, an apparently non-mosaic trisomy 7. Amniocentesis showed exclusively normal mitoses, and the pregnancy continued normally. One hundred mitoses from cord blood of the normal newborn revealed a non-mosaic 46,XX complement. No cells with a proven trisomy 7 were found in cultures from either of two biopsies of the morphologically normal placenta, but the peripheral biopsy showed in multiple cultures an abnormal clone: 47,XX, + 20,-2,-21, + t(2;21)(p13;q22). To our knowledge, this is the first case of non-mosaic trisomy 7 detected on CVS which has had follow-up studies of amniotic fluid, cord blood, and term placenta.